98%
921
2 minutes
20
Myocardial infarction (MI) is a leading global cause of mortality, necessitating novel biomarkers for early diagnosis and prognosis. This review explores circulating cell-free DNA (cfDNA) as a minimally invasive tool for MI detection, focusing on its mechanistic role, diagnostic accuracy, and potential in personalized medicine. CfDNA levels rise rapidly post-ischemic event, correlating with myocardial damage and complementing troponins. Liquid biopsies using cfDNA enable dynamic monitoring of disease progression, but methodological variability and low concentrations limit its standalone use. Standardizing protocols and integrating cfDNA into multi-marker panels could enhance its clinical utility, positioning it as a transformative cardiovascular diagnostic tool.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357262 | PMC |
http://dx.doi.org/10.1016/j.ijcrp.2025.200484 | DOI Listing |
Biochem Biophys Rep
December 2025
Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Introduction: 5-Hydroxymethyl furfural (5-HMF) is a furan compound with a molecular formula of CHO. Studies have found that 5-HMF has many pharmacological effects, such as improving hemorheology, anti-inflammatory, antioxidant activity and anti-myocardial ischemia. Identifying the preventive effect of 5-HMF against ischemic stroke and its possible mechanism was the aim of this investigation.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.
Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
Coronary microvascular disease has been found to increase the incidence of the composite endpoint for cardiovascular events and affect coronary revascularization. Coronary microvascular disease is often accompanied by epicardial disease, and despite successful revascularization and optimal medications, coronary microvascular disease may lead to reduced exercise tolerance and worsening clinical symptoms. Moreover, despite advances in percutaneous coronary intervention for coronary revascularization, the management of microvascular obstruction in reperfused myocardial tissue remains challenging and is a high-risk procedure.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Cardiology, Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, 361015 Xiamen, Fujian, China.
Background: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score represents a meaningful predictor in many cardiovascular diseases. However, the predictive utility of this score for the outcome of patients admitted to the intensive care unit (ICU) due to acute myocardial infarction (AMI) has yet to be fully elucidated.
Methods: Information from the Medical Information Mart for Intensive Care (MIMIC)-IV v3.
Rev Cardiovasc Med
August 2025
Center for Coronary Heart Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases of China, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.
Background: Globally, acute myocardial infarction (AMI) is among the primary causes of mortality. The ideal approach for blood pressure (BP) management for patients experiencing ST-segment elevation myocardial infarction (STEMI) who receive percutaneous coronary intervention (PCI) remains a topic of ongoing debate. Current guidelines on BP management lack specific recommendations for STEMI patients undergoing PCI, resulting in substantial individual variability and uncertainties in clinical treatment strategies.
View Article and Find Full Text PDF